Posting on his daily blog, Clay Siegall has waded into the Bill Belichick’s friction with Tom Brady and the owner of Patriots Robert Kraft. The coach has denied the reports by describing his relationship with the long-serving Patriots player as great. Mr. Belichick set the record straight during a press conference with reporters. The friction was said to have been caused by Kraft’s alleged involvement in player decisions by wanting the coach to trade Patriots quarterback, Jimmy Garoppolo. However, the coach has denied such reports, terming his alleged ‘furious and demoralized’ reactions to Kraft’s orders as false. He denied reading any of the written articles and said he has a good relationship with his boss. Furthermore, he appreciated the working relationship he has had with both Kraft and his longest-serving player. The Patriots coach said he cannot be made to make a trade he doesn’t want since everything at the club is handled and discussed in an organized manner. At the same time, he answered questions about his relationship with Commissioner Goodell, terming their relationship as professional and denied having any private and long meeting with him during the off week of the season. Furthermore, the coach also termed his relationship with another person mentioned in the ESPN article, Alex Guerrero, as professional.

Clay Siegall: Professional and Academic Background

Dr. Clay Siegall is the president, cofounder and chief executive officer of Seattle Genetics and holds a Ph.D. degree in Genetics from George Washington University. He also has a degree in Zoology, is a winner of the Pierce Awards, and finalist of Pacific Northwest Ernest and Young Entrepreneur of the Year award. Mr. Siegall has been Seattle Genetics chairman since 2004 and has worked in institutions like the Squibb Pharmaceuticals Research Institute in Bristol-Myers, where he worked for four years, two of which he was a Principal Scientist. For the past four years, he has been chairman at Ultragenyx Pharmaceutical and has been president of Seattle Genetics for 20 years. He boasts of more than twenty years of experience in cancer research and development of therapeutic drugs. He guided Seattle Genetics to financial success and has dedicated his life to finding a cure for cancer.